INS and obesity disorder: In a retrospective study of 51 T1D people with obesity, tirzepatide was associated with 8.5% mean Weight loss, 0.9% HbA1c reduction, and a 31.6% decrease in daily insulin dose over 8 months, with no increase in hypoglycemia; GI symptoms were the main side effect; overall tolerability was high [52].